SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Blonder Tongue Laboratories, Inc. (BDRL) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 15/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BDRL
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.01
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.09
Book Value / Share$0.00
Revenue / Share$0.77
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-1.05 |
$20.94M |
$-6.77M |
-32.3% |
| 2016 |
$-0.16 |
$22.51M |
$-1.2M |
-5.3% |
| 2017 |
$-0.05 |
$23.28M |
$-384K |
-1.6% |
| 2018 |
$-0.15 |
$21.71M |
$-1.34M |
-6.2% |
| 2019 |
$-0.08 |
$19.84M |
$-742K |
-3.7% |
| 2020 |
$0.30 |
$16.38M |
$3M |
18.3% |
| 2021 |
$0.01 |
$15.75M |
$84K |
0.5% |
| 2022 |
$-0.28 |
$18.12M |
$-3.71M |
-20.5% |
| 2023 |
$-0.15 |
$13.21M |
$-2.12M |
-16% |
| 2024 |
$-0.09 |
$11.17M |
$-1.25M |
-11.2% |
